Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
4D Molecular Therapeutics, Inc. (FDMT) had Free Cash Flow of $-91.83M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$0.01M |
|
$-54.66M |
|
-- |
|
$0.01M |
|
$59.47M |
|
$-59.46M |
|
$4.80M |
|
$-54.66M |
|
$-54.66M |
|
$-54.66M |
|
$-54.66M |
|
$-54.66M |
|
$-54.66M |
|
$-59.46M |
|
$-59.46M |
|
55.93M |
|
55.93M |
|
$-0.98 |
|
$-0.98 |
|
| Balance Sheet Financials | |
$303.29M |
|
$17.50M |
|
$170.35M |
|
$473.64M |
|
$34.68M |
|
-- |
|
$18.07M |
|
$52.75M |
|
$420.89M |
|
$420.89M |
|
$420.89M |
|
46.70M |
|
| Cash Flow Statement Financials | |
$-91.14M |
|
$18.10M |
|
$0.86M |
|
$149.34M |
|
$77.16M |
|
$-72.18M |
|
$11.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.75 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-396373.30% |
|
-396373.30% |
|
-- |
|
-364386.70% |
|
-364386.70% |
|
|
Free Cash Flow |
$-91.83M |
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-12.99% |
|
-12.99% |
|
-11.54% |
|
-12.99% |
|
$9.01 |
|
$-1.64 |
|
$-1.63 |
|